Recent News — SR One Capital Management

NOTABLE / CLINICAL AND SCIENTIFIC IMPACT / NEW INVESTMENTS / FINANCING AND PARTNERSHIPS / PEOPLE

RECENT NOTABLE NEWS

Featured

SR One Closes Second Venture Fund at $600M

Mar 27, 2023

SR One Closes Second Venture Fund at $600M

Mar 27, 2023

Mar 27, 2023

Mineralys Therapeutics prices $221M IPO

Feb 14, 2023

Mineralys Therapeutics prices $221M IPO

Feb 14, 2023

Feb 14, 2023

Nimbus Therapeutics TYK2 program to be acquired by Takeda for $4B in upfront cash and up to $2B in potential commercial milestone payments

Dec 13, 2022

Nimbus Therapeutics TYK2 program to be acquired by Takeda for $4B in upfront cash and up to $2B in potential commercial milestone payments

Dec 13, 2022

Dec 13, 2022

Arcellx announces strategic collaboration with Kite, a Gilead Company, to co-develop and co- commercialize late- stage clinical CART-ddBCMA in multiple myeloma

Dec 9, 2022

Arcellx announces strategic collaboration with Kite, a Gilead Company, to co-develop and co- commercialize late- stage clinical CART-ddBCMA in multiple myeloma

Dec 9, 2022

Dec 9, 2022

MiroBio to be acquired by Gilead Sciences for $405M

Aug 4, 2022

MiroBio to be acquired by Gilead Sciences for $405M

Aug 4, 2022

Aug 4, 2022

Ancora Biotech lead clinical asset, TeneoTwo, to be acquired by AstraZeneca for up to $1.27B

Jul 5, 2022

Ancora Biotech lead clinical asset, TeneoTwo, to be acquired by AstraZeneca for up to $1.27B

Jul 5, 2022

Jul 5, 2022

RECENT CLINICAL AND SCIENTIFIC IMPACT NEWS

Featured

Simcha Therapeutics announces first patient dosed in Ph1/2 study evaluating ST-067 in combination with KEYTRUDA® (Pembrolizumab)

Jul 6, 2023

Simcha Therapeutics announces first patient dosed in Ph1/2 study evaluating ST-067 in combination with KEYTRUDA® (Pembrolizumab)

Jul 6, 2023

Jul 6, 2023

FDA accepts biologics license applications for exagamglogene autotemcel (exa-cel) for severe sickle cell disease and transfusion-dependent beta thalassemia

Jun 8, 2023

FDA accepts biologics license applications for exagamglogene autotemcel (exa-cel) for severe sickle cell disease and transfusion-dependent beta thalassemia

Jun 8, 2023

Jun 8, 2023

HotSpot Therapeutics achieves first-in-human dosing with HST-1011, an investigational oral small molecule Allosteric Inhibitor of CBL-B

Apr 11, 2023

HotSpot Therapeutics achieves first-in-human dosing with HST-1011, an investigational oral small molecule Allosteric Inhibitor of CBL-B

Apr 11, 2023

Apr 11, 2023

HotSpot Therapeutics announces FDA clearance of IND application for HST-1011, an investigational small molecule allosteric inhibitor of CBL-B

Jan 3, 2023

HotSpot Therapeutics announces FDA clearance of IND application for HST-1011, an investigational small molecule allosteric inhibitor of CBL-B

Jan 3, 2023

Jan 3, 2023

Nimbus Therapeutics announces positive topline results for Ph2b clinical trial of allosteric TYK2 inhibitor

Nov 30, 2022

Nimbus Therapeutics announces positive topline results for Ph2b clinical trial of allosteric TYK2 inhibitor

Nov 30, 2022

Nov 30, 2022

ARS Pharmaceuticals announces FDA acceptance of NDA for neffy® (epinephrine nasal spray) for the treatment of allergic reactions (type I) including anaphylaxis

Oct 21, 2022

ARS Pharmaceuticals announces FDA acceptance of NDA for neffy® (epinephrine nasal spray) for the treatment of allergic reactions (type I) including anaphylaxis

Oct 21, 2022

Oct 21, 2022

RECENT INVESTMENTS NEWS

Featured

Rezo Therapeutics, founded by renowned UCSF scientists, raises $78M in Series A

Nov 17, 2022

Rezo Therapeutics, founded by renowned UCSF scientists, raises $78M in Series A

Nov 17, 2022

Nov 17, 2022

Ancora Biotech raises $60M in Series A

Jun 9, 2022

Ancora Biotech raises $60M in Series A

Jun 9, 2022

Jun 9, 2022

Mineralys Therapeutics raises $118M in Series B

Jun 8, 2022

Mineralys Therapeutics raises $118M in Series B

Jun 8, 2022

Jun 8, 2022

Simcha Therapeutics raises $40M in Series B

Jan 27, 2022

Simcha Therapeutics raises $40M in Series B

Jan 27, 2022

Jan 27, 2022

Nomic Bio raises $17M in Series A

Dec 8, 2021

Nomic Bio raises $17M in Series A

Dec 8, 2021

Dec 8, 2021

Odyssey Therapeutics raises $218M in Series A

Dec 7, 2021

Odyssey Therapeutics raises $218M in Series A

Dec 7, 2021

Dec 7, 2021

RECENT FINANCINGS AND PARTNERSHIPS NEWS

Featured

Nimbus Therapeutics secures $210M in private financing

Sep 6, 2023

Nimbus Therapeutics secures $210M in private financing

Sep 6, 2023

Sep 6, 2023

FORE Biotherapeutics announces $75M in Series D and CEO Transition

Aug 23, 2023

FORE Biotherapeutics announces $75M in Series D and CEO Transition

Aug 23, 2023

Aug 23, 2023

ADARx Pharmaceuticals announces oversubscribed $200M Series C

Aug 9, 2023

ADARx Pharmaceuticals announces oversubscribed $200M Series C

Aug 9, 2023

Aug 9, 2023

Simcha Therapeutics announces clinical trial collaboration with Merck to evaluate ST-067 in combination with KEYTRUDA® (Pembrolizumab)

Apr 5, 2023

Simcha Therapeutics announces clinical trial collaboration with Merck to evaluate ST-067 in combination with KEYTRUDA® (Pembrolizumab)

Apr 5, 2023

Apr 5, 2023

ADARx Pharmaceuticals raises $46M in Series B-1 and appoints Dr. Lorence Kim to Board of Directors

Jan 20, 2023

ADARx Pharmaceuticals raises $46M in Series B-1 and appoints Dr. Lorence Kim to Board of Directors

Jan 20, 2023

Jan 20, 2023

Akamis Bio raises $30M financing and relaunches with name change from PsiOxus Therapeutics

Jan 5, 2023

Akamis Bio raises $30M financing and relaunches with name change from PsiOxus Therapeutics

Jan 5, 2023

Jan 5, 2023

RECENT PEOPLE NEWS

Featured

Rezo Therapeutics appoints Nadir Mahmood as CEO

Sep 20, 2023

Rezo Therapeutics appoints Nadir Mahmood as CEO

Sep 20, 2023

Sep 20, 2023

Nkarta appoints Alyssa Levin CBO and CFO

Jul 5, 2023

Nkarta appoints Alyssa Levin CBO and CFO

Jul 5, 2023

Jul 5, 2023

ADARx Pharmaceuticals appoints Robert MacLeod as CSO

Jan 9, 2023

ADARx Pharmaceuticals appoints Robert MacLeod as CSO

Jan 9, 2023

Jan 9, 2023

Nimbus Therapeutics appoints Nathalie Franchimont as CMO

Oct 26, 2022

Nimbus Therapeutics appoints Nathalie Franchimont as CMO

Oct 26, 2022

Oct 26, 2022

ADARx Pharmaceuticals appoints Christopher Prentiss as CFO

Sep 28, 2022

ADARx Pharmaceuticals appoints Christopher Prentiss as CFO

Sep 28, 2022

Sep 28, 2022

Simcha Theraeputics accelerates growth with key leadership appointments, expanded research and option agreement with Yale School of Medicine

Aug 16, 2022

Simcha Theraeputics accelerates growth with key leadership appointments, expanded research and option agreement with Yale School of Medicine

Aug 16, 2022

Aug 16, 2022